PhaseBio Pharmaceuticals picks up $40 mln Series C
Malvern, Pennsylvania-based PhaseBio Pharmaceuticals Inc, which is focused on developing treatments for metabolic and specialty cardiopulmonary disorders, has secured $40 million in Series C funding. AstraZeneca led the round with participation from New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation – JJDC and Fletcher Spaght Ventures. In addition to the funding, Dr. Michael Gutch of AstraZeneca has been added to PhaseBio's board of directors while Donald Dwyer, also of AstraZeneca, has become a board observer.
12 March 2015•4 mins read
